ArticleInternational journal of clinical and experimental pathology2015
ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Association of Serum ELMO-3 Levels with Metastatic Status and Survival Outcomes in Non-Small Cell Lung Cancer.Current issues in molecular biology · 2026Article
- Comparative Morphological, Metabolic and Transcriptome Analyses inFrontiers in cell and developmental biology · 2022Article
- ELMO2 association with GPeerJ · 2020Article
- Article
- ELMO3 - a Negative Prognostic Marker in Minor Salivary Gland Carcinoma.Pathology oncology research : POR · 2019Article
- Down Regulation of the Expression of ELMO3 by COX2 Inhibitor Suppresses Tumor Growth and Metastasis in Non-Small-Cell Lung Cancer.Frontiers in oncology · 2019Article
- Somatic mutations in early onset luminal breast cancer.Oncotarget · 2018Article
- DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas.International journal of molecular sciences · 2018Article
- Silencing ELMO3 Inhibits the Growth, Invasion, and Metastasis of Gastric Cancer.BioMed research international · 2018Article
- Knockdown of ELMO3 Suppresses Growth, Invasion and Metastasis of Colorectal Cancer.International journal of molecular sciences · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigated the diagnostic and prognostic value of engulfment and cell motility (ELMO3) in non small cell lung cancer (NSCLC).
methodsThe expression of ELMO3 at mRNA levels were detected using reverse transcription quantitative real-time polymerase chain reaction (qRT-PCR) in 125 NSCLC patients' tissues and adjacent tissues, as well as in the serum of 125 NSCLC patients and 89 healthy controls. Then, receiver operating characteristic curve (ROC), Kaplan-Meier and Cox regression analysis were adopted to estimate the potential diagnostic and prognostic value of ELMO3, respectively.
resultsELMO3 expression level was significantly up-regulated in NSCLC patients' tissues and serum compared with controls (P<0.001). Moreover, the expression of ELMO3 was significantly associated with tumor size (P=0.020), TNM stage (P=0.017), lymph node metastasis (PP=0.045) and distance metastasis (P=0.033). ROC showed the AUC was 0.917, and the optimal cutoff value was 0.735, providing a sensitivity of 92.8% and a specificity of 84.3%. Furthermore, Kaplan-Meier analysis indicated the high expression of ELMO3 could lead to a shorter overall survival time. In multivariate analysis, ELMO3 expression (HR=3.378, 95% CI=1.326-8.587, P=0.011) was proved to be linked with the prognosis of NSCLC and might act as an independent prognostic marker.
conclusionThe over-expression of ELMO3 was a potential diagnostic and prognostic marker for NSCLC.
Indexed as
Identifiers
26191257PMC4503128W2422682167What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.